Full Breakdown
Eli Lilly’s Gene-Editing Therapy VERVE-102 Cuts LDL Cholesterol by Up to 62% in Early Trial
5/26/2026, 11:46:27 PM
Background & Context
Eli Lilly acquired Verve Therapeutics in June 2025 for up to $1.3 billion, adding a base-editing platform that deactivates target genes. VERVE-102 uses a lipid-nanoparticle delivery system to edit the PCSK9 gene in liver cells, a key regulator of LDL-C. The approach aims to provide a one-time alternative to chronic lipid-lowering drugs. Verve’s earlier candidate was discontinued after safety concerns, making the current data a pivotal test of the modality.
Core Trial Findings
In the Phase 1b “Heart-2” study, participants with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease received a single intravenous infusion of VERVE-102 at 1 mg/kg. The highest dose produced a 62 % reduction in low-density lipoprotein cholesterol (LDL-C) and a 51 %-88 % decline in circulating PCSK9 protein. No treatment-related serious adverse events were reported during the trial’s follow-up period.
Data & Statistics
- LDL-C reduction: up to 62 % (high-dose cohort)
- PCSK9 reduction: 51 %-88 % across dose levels
- Dose administered: 1 mg/kg (single infusion)
- Follow-up duration reported: 18 months of sustained LDL-C lowering
- Safety: no treatment-related adverse events
The magnitude of LDL-C reduction is comparable to that achieved by approved PCSK9 monoclonal antibodies such as Amgen’s Repatha.
Official Statements & Responses
Lilly’s corporate release emphasized that VERVE-102 deactivates the PCSK9 gene and that the LDL-C reduction suggests it could serve as a one-time treatment for hypercholesterolemia. Company highlighted that the lipid-lowering effect persisted for at least 18 months and noted the absence of serious safety signals. Lilly announced plans to advance the candidate into Phase 2 later in 2026.
Criticism & Opposition
Analysts at BMO Capital Markets expressed skepticism about the commercial case for a gene-editing cholesterol therapy. They questioned “the true market need of additional genetic medicines in these indications” and warned that “there may be better uses of capital for the company at this time.” The analysts noted competition from approved PCSK9 antibodies such as Amgen’s Repatha and emerging oral agents from Merck, raising concerns about cost-effectiveness relative to existing therapies.
Conflicting Reports & Gaps
The early study lacked a long-term comparator group, limiting conclusions about rare cardiovascular events or off-target DNA changes. The trial did not assess hard cardiovascular outcomes such as myocardial infarction or stroke. Larger studies will need to monitor for unintended genomic edits, liver toxicity, and broader safety signals, and regulators may impose stricter review if concerns arise.
Verbatim Quotes
- “supporting its potential as a one-time treatment for hypercholesterolemia.” — Eli Lilly, corporate release
- “We are skeptical about the true market need of additional genetic medicines in these indications,” — BMO Capital Markets analyst
- “We think there may be better uses of capital for the company at this time.” — BMO Capital Markets analyst
- “With effective injectable and oral lipid lowering agents approved or likely to be approved in the near term, we wonder what the opportunity for gene editing would really look like in this setting,” — BMO Capital Markets analyst
What’s Next
Lilly plans to initiate Phase 2 enrollment for VERVE-102 by the end of 2026, expanding the cohort to assess durability, safety, and cost-effectiveness relative to existing PCSK9 inhibitors. Parallel development of VERVE-201, targeting a different gene, signals a broader cardiovascular-metabolic strategy. Regulatory filings are expected to be submitted to the FDA in early 2027, with dialogue focused on long-term genomic safety and comparative efficacy.
